“Determination of the 50% Human Infectious Dose for Norwalk Virus”, J Infect Dis, vol. 209, pp. 1016-1022, 2014.
, “Direct Comparison of an Inactivated Subvirion Influenza A Virus Subtype H5N1 Vaccine Administered by the Intradermal and Intramuscular Routes”, J Infect Dis, vol. 206, pp. 1069-1077, 2012.
, “Norovirus Vaccine Against Experimental Human GII.4 Virus Illness: A Challenge Study in Healthy Adults”, J Infect Dis, vol. jiu497 [pi, 2014.
, “Norovirus Vaccine Against Experimental Human Norwalk Virus Illness”, N Engl J Med, vol. 365, pp. 2178-2187, 2011.
, , “Phase II Trial in Adults of Concurrent or Sequential 2009 Pandemic H1N1 and 2009-2010 Seasonal Trivalent Influenza Vaccinations”, Vaccine, vol. 33, pp. 163-173, 2015.
, “Rapid Research Response to the 2009 A(H1N1)pdm09 Influenza Pandemic (Revised)”, BMC Res Notes, vol. 6, 2013.
, “Safety and Immunogenicity of a Subvirion Inactivated Influenza a/H5N1 Vaccine With or Without Aluminum Hydroxide Among Healthy Elderly Adults”, Vaccine, vol. 27, pp. 5091-5095, 2009.
,